Phlexglobal Issues Industry Advisory on New EMA Trial Master File Guidance

Comprehensive guidance took effect June 6, 2019; will significantly impact sponsor and CRO compliances

shutterstock_679945117

Amersham, UK; Malvern, PA. June 20, 2019 — Phlexglobal today announced an important industry advisory around the new European Medicines Agency (EMA) guidance on Trial Master Files. The guidance took effect on June 6, 2019, and promises to have far-reaching impacts on an organization’s TMF processes, technology, and best practices – as well as related departments and systems.

 

 

Digital Brain Header Large Brain Right

It's time to raise your standard 

CONTACT PHLEXGLOBAL TODAY
 
Contact Us

Latest News

A Day in the Life: TMF Team – What Type of TMF Resource Do You Actually Need?

Building the Right TMF Team for Inspection Readiness, Scalability and Growth As clinical trials become more complex, many Sponsors and CROs find themselves asking the same question: Do we need more

A Day in the Life: TMF Program Lead - The Hidden Cost of Managing Studies One at a Time

Why portfolio-level TMF oversight is becoming a necessity, not a luxury. The Problem With Thinking Study-by-Study Clinical trials do not happen in isolation. Sponsors and CROs are running multiple

A Day in the Life: Senior TMF Study Owner - Why Growing Portfolios Need Senior TMF Leadership

How Senior TMF Study Owners bridge strategy, mentoring and operational delivery. What does it really mean to have an expert in your corner when it comes to your Trial Master File? For organisations